AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...

for the treatment of generalized anxiety disorder, in a Phase 2 trial conducted in the United States and United Kingdom, and IHL-675A, an oral fixed dose combination of cannabidiol and ...

We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

Most of us have experienced anxiety or will at some point in the future. It's normal to feel worried from time to time.

A prescription digital therapeutic for insomnia was associated with significant improvements in sleep, depression, and anxiety.

Global Cannabis Use Disorder Treatment Market. The global cannabis use disorder treatment market is expected to grow from USD ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

Maybe it was situational anxiety like feeling nervous the night before a big interview or moments before public speaking to a crowd. Or, it was long-term anxiety like generalized anxiety disorder (GAD ...

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...